Skip to main content
OpenTrials
Completed

NCT Number: NCT04586621

Evaluation of the Performance and Safety of the Atoldys/ Lexilens Glasses Developed to Improve the Reading of Dyslexic Subjects

The aim of this study is to evaluate the efficacy and safety of a new medical device (Atoldys/ Lexilens glasses) on the improvement of reading skills of young dyslexic subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year–13 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr Laurence Derieux, Caen, France

Loading trial locations.

About this study

Dyslexia is defined as a specific learning disability that is characterized by reading difficulties, in the absence of intellectual disability, neurological or psychiatric disorder, uncorrected sensory disturbance (sight, hearing) or an educational deficiency.

Dyslexia appears in the child from the earliest stages of learning in the form of a difficulty in mastering the learning of reading. This disorder is manifested by a generally hesitant reading, slowed down, full of errors, requiring a lot of effort for the child and may impact his reading comprehension. The dyslexia-related deficiency is of variable intensity depending on the individual; it may be accompanied by calculus disorders (dyscalculia), oral language (dysphasia), motor coordination (dyspraxia) or attention disorders with or without hyperactivity. In nearly 40% of cases, a child affected by Dys disorders presents several learning disorders.

To date, the causes of dyslexia are not yet clearly established. The wide variety of symptoms and disorders associated with dyslexia does not facilitate the identification of precise neurobiological / psycho cognitive mechanisms. There are therefore several theories: phonological, visual, temporal, cerebellar or proprioceptive auditory processing.

Recently, following work published in 2017, an anatomical cause based on Maxwell's spots could also be a cause of dyslexia.

The aim of this study is to evaluate a new medical device (class I CE marked) to compensate this probable anatomical cause: the Atoldys/ Lexilens glasses

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Schooled in CM1, CM2 or 6ème,
  • French mother tongue,
  • For whom developmental dyslexia has been diagnosed by a health professional who specializes in this learning disorder,
  • With near vision, without optical correction, equivalent to P5 or better according to the Parinaud scale (distance: 30-40 cm),
  • Presenting an IQ ≥ 80 and ≤130 according to the WISC-V test performed by a psychologist,
  • For whom a written consent was obtained regarding his study participation.

Exclusion criteria

  • With medical history or presenting a neurological pathology,
  • Presenting a developmental disorder (autism, ADHD, ...),
  • Presenting hearing disorders,
  • Presenting an astigmatism of more than one uncorrected diopter,
  • Presenting other visual disorders,
  • Any other condition that, in the opinion of health professionals, could impair its ability to complete the study or could pose a significant risk.

Treatment and study plan

Atoldys/ Lexilens - SHAM

Device

Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency

SHAM- Atoldys/ Lexilens

Device

SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency

Primary outcomes

  1. Reading performance aloud of a text with french E.L.FE Test

    Time frame: 1 day

    E.L.FE Test (=Evaluation de la Lecture en FluencE) - "Monsieur Petit" and "Le Géant égoïste" texts : percentile

Secondary outcomes

  1. Reading performance aloud of isolated words with french BALE Test

    Time frame: 1 day

    BALE test (=Batterie Analytique de Langage Ecrit): percentile

  2. Security: incidence of Adverse Events

    Time frame: 1 day

    By questioning the child & the speech therapist - evaluation of adverse effects due to glasses (Yes/ No): headache, nausea, dizziness, fatigue and eye fatigue. According to patient questioning and clinical exam, the Adverse Event Table will be completed (description, dates, severity, imputability, action,...).

  3. Security: device deficiencies

    Time frame: 1 day

    By questioning the speech therapist - evaluation of deficiencies due to glasses: the device deficienciesTable will be completed (description, relation with adverse effect, taken measures,...).

  4. Child's satisfaction regarding reading fluency and comprehension

    Time frame: 1 day

    Child interview with numeric scale (0-10) and yes/ no answer

  5. Speech therapist's satisfaction regarding Securirty, Performance and Usability of glasses

    Time frame: 1 day

    speech therapist interview with 4 points - Likert scale (Very good, Good, Moderate, Bad)

Sponsors and collaborators

Lead sponsor

ABEYE

Industry

Collaborators

  • Slb Pharma

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Oct 14, 2020
Registry last updated
Feb 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.